MX2016008478A - Nuevo anticuerpo anti adam17 y su uso en el tratamiento del cancer. - Google Patents

Nuevo anticuerpo anti adam17 y su uso en el tratamiento del cancer.

Info

Publication number
MX2016008478A
MX2016008478A MX2016008478A MX2016008478A MX2016008478A MX 2016008478 A MX2016008478 A MX 2016008478A MX 2016008478 A MX2016008478 A MX 2016008478A MX 2016008478 A MX2016008478 A MX 2016008478A MX 2016008478 A MX2016008478 A MX 2016008478A
Authority
MX
Mexico
Prior art keywords
cancer
antibody
treatment
adam17
novel anti
Prior art date
Application number
MX2016008478A
Other languages
English (en)
Inventor
Lowe Peter
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of MX2016008478A publication Critical patent/MX2016008478A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

La presente invención se refiere a un nuevo anticuerpo capaz de unirse al ADAM17 y también las secuencias decodificadoras de aminoácidos y ácidos nucleicos de dicho anticuerpo. En un aspecto, la invención se refiere a un nuevo anticuerpo o fragmentos ligantes de antigenos, capaces de unirse al ADAM17 con actividades antitumorales. La invención también comprende el uso de dicho anticuerpo como un fármaco para el tratamiento del cáncer. Finalmente, la invención comprende composiciones que comprenden dicho anticuerpo, solo o en combinación o conjugado con otros compuestos contra el cáncer, y el uso de los mismos para el tratamiento del cáncer.
MX2016008478A 2013-12-24 2014-12-24 Nuevo anticuerpo anti adam17 y su uso en el tratamiento del cancer. MX2016008478A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13306860 2013-12-24
PCT/EP2014/079315 WO2015097287A1 (en) 2013-12-24 2014-12-24 Novel anti adam17 antibody and its use for the treatment of cancer

Publications (1)

Publication Number Publication Date
MX2016008478A true MX2016008478A (es) 2017-01-11

Family

ID=49920097

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016008478A MX2016008478A (es) 2013-12-24 2014-12-24 Nuevo anticuerpo anti adam17 y su uso en el tratamiento del cancer.

Country Status (13)

Country Link
US (1) US20160326257A1 (es)
EP (1) EP3086808B1 (es)
JP (1) JP2017501723A (es)
KR (1) KR20160093723A (es)
CN (1) CN106029094A (es)
AR (1) AR098953A1 (es)
AU (1) AU2014372539A1 (es)
BR (1) BR112016014882A2 (es)
CA (1) CA2935003A1 (es)
MX (1) MX2016008478A (es)
RU (1) RU2016129198A (es)
TW (1) TW201609814A (es)
WO (1) WO2015097287A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10858441B2 (en) * 2017-07-12 2020-12-08 University Of Macau Method of treatment for pancreatic cancer by administering a human-mouse cross-reactive ADAM 17 antibody
CN111040032B (zh) * 2018-10-11 2022-11-25 中国科学院上海营养与健康研究所 双向调节素在制备细胞衰老及肿瘤的诊断或调控制剂中的应用
US20230159653A1 (en) * 2019-03-08 2023-05-25 Memorial Sloan Kettering Cancer Center Adam17 binding molecules and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2591659A1 (en) * 2004-12-17 2006-06-22 Monash University Regulation of metalloprotease cleavage of cell surface proteins
US9150659B2 (en) * 2011-02-01 2015-10-06 Gillian Murphy Anti-tace antibody molecules and their uses

Also Published As

Publication number Publication date
US20160326257A1 (en) 2016-11-10
JP2017501723A (ja) 2017-01-19
CA2935003A1 (en) 2015-07-02
EP3086808A1 (en) 2016-11-02
RU2016129198A (ru) 2018-01-30
AU2014372539A1 (en) 2016-07-21
WO2015097287A1 (en) 2015-07-02
AR098953A1 (es) 2016-06-22
KR20160093723A (ko) 2016-08-08
TW201609814A (zh) 2016-03-16
BR112016014882A2 (pt) 2017-09-19
EP3086808B1 (en) 2018-09-19
RU2016129198A3 (es) 2018-08-21
CN106029094A (zh) 2016-10-12

Similar Documents

Publication Publication Date Title
PH12019501393A1 (en) Afucosylated anti-fgfr2iiib antibodies
PH12018502225A1 (en) Anti-il-33 antibodies, compositions, methods and uses thereof
MX2014009289A (es) Anticuerpos c1orf32 y usos de los mismos para el tratamiento del cancer.
MX2014015830A (es) Anticuerpos lsr y usos de los mismos para el tratamiento de cancer.
WO2014004549A3 (en) Anti-mesothelin binding proteins
MX2018000147A (es) Moleculas de anticuerpo que se unen al grupo de diferenciacion 45 (cd45).
TN2015000247A1 (en) Bcma antigen binding proteins
TN2015000396A1 (en) Antibody drug conjugates
PH12015500390A1 (en) Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis
PH12014502406A1 (en) Anti-il-23p19 antibodies
MX2014014678A (es) Molecula de union al antigeno especifico para el tejido objetivo.
EA201490644A1 (ru) Терапевтические пептиды
PH12014501410A1 (en) Compositions and methods for antibodies targeting factor p
MD20160130A2 (ro) Anticorpi umanizaţi contra CEACAM1
MX2014001766A (es) Anticuerpos de neuregulina y sus usos.
MX2022000242A (es) Anticuerpos contra ticagrelor y metodos de uso.
MX2016008478A (es) Nuevo anticuerpo anti adam17 y su uso en el tratamiento del cancer.
MX2017008475A (es) Novedoso anticuerpo humanizado adam17.
SA517390221B1 (ar) Igf-1r الجسم المضاد لـ واستخدامه في تشخيص سرطان
TN2014000207A1 (en) Anti il-36r antibodies